Table IV.
Association between the co expression of ILT4/HLA-G and clinicopathological characteristics in human CRC tissues.
| ILT4+/HLA-G+ | ILT4 /HLA-G−
|
ILT4+/HLA-G−
|
ILT4 /HLA-G+
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical parameters | N | n | χ2 | P1 | n | χ2 | P2 | n | χ2 | P3 |
| Age (year) | ||||||||||
| ≤65 | 16 | 6 | 0.247 | 0.619 | 8 | 0.909 | 0.340 | 6 | 4.140 | 0.042a |
| >65 | 28 | 14 | 8 | 2 | ||||||
| Sex | ||||||||||
| Male | 39 | 13 | 5.042 | 0.025a | 13 | 0.554 | 0.457 | 3 | 11.396 | 0.001b |
| Female | 5 | 7 | 3 | 5 | ||||||
| Primary tumor localization | ||||||||||
| Right sided | 11 | 4 | 0.283 | 0.868 | 5 | 1.316 | 0.518 | 4 | 4.326 | 0.115 |
| Left sided | 18 | 8 | 8 | 4 | ||||||
| Rectum | 15 | 8 | 3 | 0 | ||||||
| Tumor size (cm) | ||||||||||
| ≤5 | 29 | 11 | 0.698 | 0.403 | 8 | 1.256 | 0.262 | 4 | 0.739 | 0.390 |
| >5 | 15 | 9 | 8 | 4 | ||||||
| Tumor differentiation | ||||||||||
| Mediate low/low | 17 | 10 | 0.728 | 0.394 | 10 | 2.700 | 0.100 | 4 | 0.363 | 0.547 |
| High/mediate | 27 | 10 | 6 | 4 | ||||||
| Lymph node metastasis | ||||||||||
| − | 21 | 15 | 4.156 | 0.041a | 5 | 1.297 | 0.255 | 7 | 4.309 | 0.038a |
| + | 23 | 5 | 11 | 1 | ||||||
| TNM stage groupings | ||||||||||
| I/II | 15 | 10 | 1.462 | 0.227 | 13 | 10.484 | 0.001b | 6 | 4.705 | 0.030a |
| III/IV | 29 | 10 | 3 | 2 | ||||||
Tumor tissues were classified according to the AJCC Cancer Staging Manual (21).
a
P<0.05 and
b
P<0.01. TNM tumor node metastasis, ILT4 immunoglobulin like transcript 4, HLA-G human leukocyte antigen G; P1, P-value for the significance between the ILT4+/HLA-G+ and ILT4-/ HLA-G groups; P2, P-value for the significance be-tween the ILT4+/HLA-G+ and ILT4+/HLA-G- groups; P3, P-value for the significance between the ILT4+/HLA-G+ and ILT4 /HLA-G+ groups.